Aplos Medical

Aplos Medical is a clinical-stage medical device company pioneering a novel, minimally invasive implant for gastroesophageal reflux disease (GERD). Its lead product, the Omega PF™, is a small, Ω-shaped device designed to be implanted laparoscopically to prevent acid reflux while aiming to minimize common side effects like dysphagia. The company has achieved key regulatory milestones, including FDA Investigational Device Exemption (IDE) approval and patents in major markets, and is actively seeking investment partners to fund its ongoing clinical studies. With a veteran management team boasting experience in bringing over 200 products to market, Aplos is positioning its technology as a 'turning point' in the multi-billion dollar GERD treatment landscape.

Omega PF™, a small, Ω-shaped implantable device designed for laparoscopic placement to mechanically prevent gastric reflux while aiming to preserve normal swallowing function.

Aplos competes in the GERD treatment space against dominant pharmaceutical companies (PPI manufacturers) and established surgical options like Nissen fundoplication and the recently reintroduced LINX device. Its competitive edge hinges on proving a superior side-effect profile, particularly reduced dysphagia, compared to existing surgical interventions.